Ann Oncol. 2012;23(8):2065-2071.
Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy.
제1저자 김남주 · 교신저자 이근욱
소속 (9)
- Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam.
- Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul.
- Department of Surgery.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam.
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul.
- Department of Ophthalmology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul.
- Department of Ophthalmology, Hallym University Sacred Heart Hospital, Anyang, Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam. Electronic address: hmodoctor@hanmail.net.
Abstract
BACKGROUND This study was conducted to determine the incidence and clinical characteristics of lacrimal drainage obstruction (LDO) in patients receiving S-1 chemotherapy.
PATIENTS AND METHODS Consecutive 170 patients with gastric cancer who underwent curative surgery and received adjuvant S-1 chemotherapy were enrolled. S-1 was administered orally (40 mg/m2 b.i.d. on days 1-28 every 6 weeks) for 1 year. Ophthalmologic examinations were carried out on patients complaining of epiphora.
RESULTS Thirty-one patients (18%) developed epiphora. Among 31 patients, 25 underwent ophthalmologic examinations and 22 (88%) were diagnosed with LDO. The median time to the onset of LDO was 2.9 months. The most common site of obstruction was the nasolacrimal duct [86% (19/22)]; punctal [23% (5/22)] and canalicular obstruction [14% (3/22)] were also noted. In multivariate analysis, total gastrectomy [versus partial gastrectomy: hazard ratio (HR), 2.9; P=0.014] and creatinine clearance<50 ml/min (versus ≥50 ml/min: HR, 2.9; P=0.038) were independent risk factors for the development of LDO.
CONCLUSION Considering the high incidence of LDO in patients receiving S-1 chemotherapy, oncologists should be alert to epiphora and cooperate with ophthalmologists in the early stages to improve the quality of life of patients and avoid more complicated ophthalmologic procedures.
그 밖의 정보
- 출판 형태
- Journal Article
- 저널
- Annals of oncology : official journal of the European Society for Medical Oncology · eISSN 1569-8041
- 전자 출판
- 2012-05-15
- MeSH
- Adult · Aged · Antimetabolites, Antineoplastic / administration & dosage / adverse effects · Antineoplastic Combined Chemotherapy Protocols / administration & dosage / adverse effects · Drug Combinations · Female · Humans · Lacrimal Duct Obstruction / chemically induced / pathology · Male · Middle Aged · Nasolacrimal Duct / drug effects / pathology · Oxonic Acid / administration & dosage / adverse effects · Stomach Neoplasms / drug therapy / surgery · Tegafur / administration & dosage / adverse effects
- Substances
- Antimetabolites, Antineoplastic · Drug Combinations · S 1 (combination) · Tegafur · Oxonic Acid